Funding agencies: Michael J. Fox Foundation (MJFF); Northwestern Memorial Foundation Dixon Priority award.
Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
Version of Record online: 30 SEP 2013
© 2013 Movement Disorder Society
Volume 28, Issue 13, pages 1823–1831, November 2013
How to Cite
Parkinson Study Group (2013), Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov. Disord., 28: 1823–1831. doi: 10.1002/mds.25639
Relevant conflicts of interest/financial disclosures: J.D. Surmeier has a pending use patent for the use of dihydropyridine compounds in Parkinson's disease. The rest of the authors have nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
Members of the Parkinson Study Group are listed in the Appendix.
- Issue online: 13 NOV 2013
- Version of Record online: 30 SEP 2013
- Manuscript Accepted: 4 JUN 2013
- Manuscript Revised: 30 MAY 2013
- Manuscript Received: 17 APR 2013
Additional Supporting Information may be found in the online version of this article.
|mds25639-sup-0001-supptable1.doc||32K||Supplementary Table 1. Change in the vital signs between baseline and final visit|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.